You are here

bladder cancer

Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo

Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo

BioSpace

urothelial cancer

clinical trials

Flag link:

Royalty Pharma to Pay Potential $500M for Royalties on Ferring’s Gene Therapy

Royalty Pharma to Pay Potential $500M for Royalties on Ferring’s Gene Therapy

BioSpace

Ferring Pharmaceuticals

Flag link:

CG brings back the crossover round, reeling in $105M to fund phase 3 bladder cancer trial

CG brings back the crossover round, reeling in $105M to fund phase 3 bladder cancer trial

Fierce Biotech

clinical trials

Flag link:

Urogen's Potential First Non-Surgical Therapy for LG-IR-NMIBC Posts Promising Phase 3 Trial Data

Urogen's Potential First Non-Surgical Therapy for LG-IR-NMIBC Posts Promising Phase 3 Trial Data

Benzinga

clinical trials

non-muscle invasive bladder cancer

Flag link:

Bristol Myers' Opdivo stages comeback in bladder cancer, teeing up 2 'Merck' showdowns

Bristol Myers' Opdivo stages comeback in bladder cancer, teeing up 2 'Merck' showdowns

Fierce Pharma

Bristol Myers Squibb

Flag link:

Ferring, with manufacturing update, takes a step towards first gene therapy sales

Ferring, with manufacturing update, takes a step towards first gene therapy sales

BioPharma Dive

Ferring Pharmaceuticals

Flag link:

Lilly, Takeda Face Class-Action Racketeering Lawsuit Over Diabetes Drug

Lilly, Takeda Face Class-Action Racketeering Lawsuit Over Diabetes Drug

BioSpace

Flag link:

ASCO: Johnson & Johnson's Balversa tops chemotherapy in bladder cancer trial

ASCO: Johnson & Johnson's Balversa tops chemotherapy in bladder cancer trial

Fierce Pharma

Flag link:

AstraZeneca study points to new uses for targeted cancer drug Enhertu

AstraZeneca study points to new uses for targeted cancer drug Enhertu

BioPharma Dive

cervical cancer

Flag link:

Immunitybio slumps as FDA declines to approve bladder cancer treatment

Immunitybio slumps as FDA declines to approve bladder cancer treatment

NASDAQ

Flag link:

GSK's bellwether Zantac court date pushed to July

GSK's bellwether Zantac court date pushed to July

Endpoints

Flag link:

A renewed push into early bladder cancer

A renewed push into early bladder cancer

EP Vantage

Ferring Pharmaceuticals

Flag link:

Ferring wins FDA approval for bladder cancer gene therapy

Ferring wins FDA approval for bladder cancer gene therapy

BioPharma Dive

Ferring Pharmaceuticals

Flag link:

UroGen reports data from Phase IIb trial of bladder cancer treatment

UroGen reports data from Phase IIb trial of bladder cancer treatment

Clinical Trials Arena

clinical trials

Flag link:

Roche Withdraws Tecentric for Bladder Cancer Indication

Roche Withdraws Tecentric for Bladder Cancer Indication

BioSpace

metastatic bladder cancer

Flag link:

A startup plans an IPO to give a shelved Lilly drug another shot

A startup plans an IPO to give a shelved Lilly drug another shot

BioPharma Dive

Acrivon Therapeutics

endometrial cancer

precision medicine

Flag link:

Modified bladder cancer treatment shows promise

Modified bladder cancer treatment shows promise

Drugs.com

Texas Biomedical Research Institute

Flag link:

ImmunityBio’s Bladder Cancer Immunotherapy BLA gets FDA Nod

ImmunityBio’s Bladder Cancer Immunotherapy BLA gets FDA Nod

BioSpace

Flag link:

Seagen, Astellas claim positive results in study key to cancer drug's success

Seagen, Astellas claim positive results in study key to cancer drug's success

BioPharma Dive

clinical trials

Flag link:

Sesen slams brakes on phase 3 bladder cancer program to save cash as it looks for off-ramp

Sesen slams brakes on phase 3 bladder cancer program to save cash as it looks for off-ramp

Fierce Biotech

clinical trials

Flag link:

Pages